All patients self-identified as non-White and nearly 69% of treated subjects had objectively measured Fitzpatrick skin types IV through VI The IL-23 inhibitor guselkumab demonstrated efficacy out to 100 weeks in the treatment of psoriasis across a spectrum of skin types, according to poster research presented at the 2026 annual meeting of the American Academy of Dermatology (AAD) in Denver. A full report will be published in the June 2026 issue of The Chronicle of Skin & Alle

There is still time to submit applications for the third annual C anadian Skin of Colour & Diversity Research Scholarship Program for...

There is just over one week until the 4th annual Colloquium on the Black Patient in Dermatology on Aug. 9, 2025, from 10:00 a.m. to 1:00...

Ethnodermatology.com , the online portal for Skin Spectrum™ Quarterly: The Journal of Ethnodermatology ,™ is now live. In an increasingly...

Submissions are being accepted for the third annual Canadian Skin of Colour & Diversity Research Scholarship Program for dermatology residents, supported by Pfizer Canada . As part of our mutual commitment to empower dermatologists to elevate Canadian healthcare and knowledge, an independent committee of dermatologists seeks applications from Canadian dermatology residents across the country who have innovative projects to propose to address care gaps within skin diseases in

Dr. Emil A. Tanghetti, Photo courtesy of the American Society for Laser Medicine and Surgery A recent study highlights a significant...

A new study from Northwestern University in Chicago has identified a concerning trend in the accuracy of skin disease diagnosis across...

Dr. Tashmeeta Ahad has been awarded the first Dr. Mercy Alexis Research Grant in Skin of Color Dermatology for her project on...